A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway

Aberrant activation of the classical complement pathway is the common underlying pathophysiology of orphan diseases such as bullous pemphigoid, antibody‐mediated rejection of organ transplants, cold agglutinin disease, and warm autoimmune hemolytic anemia. Therapeutic options for these complement‐me...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartko, Johann, Schoergenhofer, Christian, Schwameis, Michael, Firbas, Christa, Beliveau, Martin, Chang, Colin, Marier, Jean‐Francois, Nix, Darrell, Gilbert, James C., Panicker, Sandip, Jilma, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175298/
https://www.ncbi.nlm.nih.gov/pubmed/29737533
http://dx.doi.org/10.1002/cpt.1111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175298/
https://www.ncbi.nlm.nih.gov/pubmed/29737533
http://dx.doi.org/10.1002/cpt.1111

Ejemplares similares